FFPRHC Guidance emergency contraception (April 2003)

Journal of Family Planning and Reproductive Health Care

Volumn 29, Issue 2, 2003, Pages 9-15

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; AZITHROMYCIN; COPPER INTRAUTERINE DEVICE; DOMPERIDONE; DOXYCYCLINE; ESTROGEN; GESTAGEN; LEVONELLE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; WARFARIN;

ANTIBIOTIC PROPHYLAXIS; CLINICAL TRIAL; CONDOM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUNSELING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; ECTOPIC PREGNANCY; EMERGENCY HEALTH SERVICE; EXTRAPYRAMIDAL SYMPTOM; FAMILY PLANNING; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH SERVICE; HORMONAL CONTRACEPTION; HUMAN; IMPLANT; INFECTION; INTRAUTERINE CONTRACEPTIVE DEVICE; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; NATIONAL HEALTH SERVICE; NAUSEA; NULLIPARA; ORAL CONTRACEPTION; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREGNANCY RATE; PREGNANCY TEST; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; TREATMENT FAILURE; VOMITING;

EID: 0038335987     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118903101197458     Document Type: Review

References (53)

1. Faculty of Family Planning and Reproductive Health Care. Emergency contraception: recommendations for clinical practice, April 2000.
2. Turner AN, Ellertson C. How safe is emergency contraception? Drug Saf 2002; 25: 695-706.
3. Task Force on Postovulatory Methods of Fertility Regulation. Randomized controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998; 352(9126): 428-433.
4. Ho PC, Kwan MSW. A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception. Hum Reprod 1993; 8: 389-392.
5. PRODIGY Guidance: contraception - emergency. London: Department of Health, 2001. www.prodigy.nhs.uk
6. Ashok PW, Stalder C, Wagaarachchi PT, et al. A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. Br J Obstet Gynaecol 2002; 109: 553-560.
7. von Hertzen H, Piaggio G, Ding J, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 360: 1803-1810.
8. Cheng L, Gulmezoglu AM, Ezcurra E, et al. Interventions for emergency contraception (Cochrane Review). The Cochrane Library 2002: 4.
9. Tremblay D, Gainer E, Ulmann A. The pharmacokinetics of 750 μg levonorgestrel following administration of one single dose or two doses at 12- or 24-h interval. Contraception 2001; 64: 327-331.
10. Levonelle: summary of product characteristics. www.levonelle.co.uk
11. Bhattacharjee SK, Romeo J, Kononova ES, et al. Postcoital contraception with levonorgestrel during the peri-ovulatory phase of the menstrual cycle. Contraception 1987; 36: 275-286.
12. World Health Organization (WHO). Selected practice recommendations for contraceptive use. Geneva: WHO, 2002.
13. Wilson JV. A New Zealand randomised comparative study of the IUDs (Nova T, MLCu375, MLAgCu375): 1, 2 and 3 year results. Adv Contracept 1992; 82: 153-159.
14. Task Force on the Safety and Efficacy of Fertility Regulating Methods. WHO Special Programme of Research, Development and Research Training in Human Reproduction. The Cu380A, TCu220C, Multiload 250 and Nova T IUD at 3, 5 and 7 years of use - results from three randomised multi-centre trials. Contraception 2002; 42: 141-158.
15. British Medical Association and the Royal Pharmaceutical Society of Great Britain, British National Formulary 43. Wallingford: Pharmaceutical Press, 2002.
16. Ellison J, Thomson AJ, Greer IA. Apparent interaction between warfarin and levonorgestrel used for emergency contraception. BMJ 2000: 321(7273): 1382-1383.
17. Persona: product description. 2003. www.persona.org.uk
18. World Health Organization (WHO). Emergency contraception: a guide to the provision of services. Geneva: WHO, 1998.
19. Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation - effects on the probability of conception, survival of the pregnancy and sex of the baby. N Engl J Med 1995; 333(23): 1517-1521.
20. Stirling A, Glasier A. Estimating the efficacy of emergency contraception - how reliable are the data? Contraception 2002; 66: 19-22.
21. Piaggio G, von Hertzen H, Grimes DA, et al. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Lancet 1999: 353: 721.
22. Liying Z, Bilian X. Emergency contraception with Multiload Cu-375 SL IUD: a multicentre clinical trial. Contraception 2001; 64: 107-112.
23. Van Look P, Stewart F. Emergency contraception. In: Hatcher R, et al. (eds), Contraceptive technology (17th edn). New York, NY: Ardent Media, 1998.
24. Wilcox AJ, Dunson DB, Weinberg CR, et al. Likelihood of conception with a single act of intercourse: providing benchmark rates for assessment of post-coital contraceptives. Contraception 2001; 63: 211-215.
25. Elomaa K, Rolland R, Brosens I, et al. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation. Am J Obstet Gynecol 2002; 179: 41-46.
26. Landgren BM, Csemiczky G. The effect on follicular growth and luteal function of "missing the pill". A comparison between a monophasic and a triphasic combined oral contraceptive. Contraception 1991; 43: 149-159.
27. World Health Organization (WHO). Improving access to quality care in family planning, medical eligibility criteria for contraceptive use. Geneva: WHO, 2000.
28. Doll H, Vessey M, Painter R. Return of fertility in nulliparous women after discontinuation of the intrauterine device: comparison with women discontinuing other methods of contraception Br J Obstet Gynaecol 2001; 108: 304-314.
29. Fotherby K. Levonorgestrel: clinical pharmacokinetics. Clin Pharmacokinet 1995; 28: 203-215.
30. Chief Medical Officer. Levonelle/Levonelle 2 emergency contraception: new advice. 35, 2003.
31. Grimes D. Intrauterine device and upper-genital tract infection. Lancet 2000; 356: 1013-1019.
32. Farley TNM, Rosenberg MJ, Rose PJ, et al. Intrauterine contraceptive devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339: 785-788.
33. Scottish Intercollegiate Guidelines Network (SIGN) Guideline. Management of genital Chlamydia trachomatis infection. 42, 2002.
34. Expert Advisory Group Report on Chlamydia trachomatis. Chief Medical Officer. 1998.
35. Kettle H, Cay S, Brown A, et al. Screening for Chlamydia trachomatis infection is indicated for women under 30 using emergency contraction. Contraception 2002; 66: 251-253.
36. Sherman CA, Harvey SM, Beckman LJ, et al. Emergency contraception: knowledge and attitudes of health care providers in a health maintenance organization. Womens Health Issues 2001; 11: 448-457.
37. Beckman LJ, Harvey SM, Sherman CA, et al. Changes in providers' views and practices about emergency contraception with education. Obstet Gynecol 2001; 97: 942-946.
38. Marshall J, Edwards C, Lambert M. Administration of medicines by emergency nurse practitioners according to protocols in an accident and emergency department. J Accid Emerg Med 1997; 14: 233-237.
39. Brittain D. Establishing all educational programme for nurses to supply emergency hormonal contraception (combined method) to protocol. Br J Fam Plann 1999; 25: 118-121.
40. The Prescription Only Medicines (Human Use) Amendment Order 2000. Statutory Instrument 2000 No. 1917.
41. Department of Health. Review of prescribing, supply and administration of medicines: a report on the supply and administration of medicines under group protocols. London: Department of Health, 1998.
42. Folkes L, Graham A, Weiss M. A qualitative study of the views of women aged 18-29 on over-the-counter availability of hormonal emergency contraception. J Fam Plann Reprod Health Care 2001; 27:189-192.
43. Iversen L, Mollison J, MacLeod TNN. Attitudes of the general public to the expanding role of community pharmacists: a pilot study. Fam Pract 2001; 18: 534-536.
44. Royal Pharmaceutical Society of Great Britain. Practice guidance on the supply of emergency hormonal contraception as a pharmacy medicine. Pharm J 2000; 265(7127): 890-892.
45. Glasier A, Baird D. The effects of self-administering emergency contraception. N Engl J Med 1998; 339: 1-4.
46. Ellertson C, Ambardekar S, Hedley A, et al. Emergency contraception: randomized comparison of advance provision and information only. Obstet Gynecol 2001; 98: 570-575.
47. Shelton JD. Repeat emergency contraception: facing our fears. Contraception 2002; 66: 15-17.
48. Croxatto HB. Emergency contraception pills: how do they work? IPPF Medical Bulletin, 2002; 36: 1-2.
49. Durand M, del Carmen Cravioto M, Raymond EG, et al. On the mechanisms of short-term levonorgestrel administration in emergency contraception. Contraception 2001; 64: 227-234.
50. Hapangama D, Glasier AF, Baird DT. The effects of peri-ovulatory administration of levonorgestrel on the menstrual cycle. Contraception 2001; 63: 123-129.
51. Marions L, Hultenby K, Lindell I, et al. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet Gynecol 2002; 100: 65-71.
52. Department of Health. Judicial review of emergency contraception. London: Department of Health, 2002.
53. Trussell J, Koenig J, Ellertson C, et al. Preventing unintended pregnancy: the cost-effectiveness of three methods of emergency contraception. Am J Public Health 1997; 87: 932-937.